Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 564098, 12 pages
http://dx.doi.org/10.1155/2015/564098
Review Article

Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored

1Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Changchun 130000, China
2Department of Neurology, Heilongjiang Provincial Hospital, Harbin, China
3Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden

Received 28 June 2015; Revised 23 August 2015; Accepted 24 August 2015

Academic Editor: Jagadeesh Bayry

Copyright © 2015 Ying Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. C. Tam, L. C. Rodrigues, I. Petersen, A. Islam, A. Hayward, and S. J. O'Brien, “Incidence of Guillain-Barré syndrome among patients with Campylobacter infection: a general practice research database study,” Journal of Infectious Diseases, vol. 194, no. 1, pp. 95–97, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Nachamkin, B. M. Allos, and T. Ho, “Campylobacter species and Guillain-Barré syndrome,” Clinical Microbiology Reviews, vol. 11, no. 3, pp. 555–567, 1998. View at Google Scholar · View at Scopus
  3. B. van den Berg, C. Walgaard, J. Drenthen, C. Fokke, B. C. Jacobs, and P. A. van Doorn, “Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis,” Nature Reviews Neurology, vol. 10, no. 8, pp. 469–482, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. H.-L. Zhang, X.-Y. Zheng, and J. Zhu, “Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis,” Cytokine and Growth Factor Reviews, vol. 24, no. 5, pp. 443–453, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M.-O. Lu and J. Zhu, “The role of cytokines in Guillain-Barré syndrome,” Journal of Neurology, vol. 258, no. 4, pp. 533–548, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. C. Hughes and D. R. Cornblath, “Guillain-Barré syndrome,” The Lancet, vol. 366, no. 9497, pp. 1653–1666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Brettschneider, A. Petzold, S. Süssmuth, and H. Tumani, “Cerebrospinal fluid biomarkers in Guillain-Barré syndrome—where do we stand?” Journal of Neurology, vol. 256, no. 1, pp. 3–12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Reiber, “Dynamics of brain-derived proteins in cerebrospinal fluid,” Clinica Chimica Acta, vol. 310, no. 2, pp. 173–186, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Islam, A. van Belkum, J. A. Wagenaar et al., “Comparative genotyping of Campylobacter jejuni strains from patients with Guillain-Barré syndrome,” PLoS ONE, vol. 4, no. 9, Article ID e7257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Jiang, M.-J. Zhang, R.-C. Liu, X.-Y. Tian, Y.-X. Gu, and J.-Z. Zhang, “Characteristics of lipo-oligosaccharide loci of Campylobacter jejuni isolates associated with Guillain-Barré syndrome from Hebei, China,” International Journal of Molecular Sciences, vol. 11, no. 3, pp. 1155–1161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. P. C. R. Godschalk, M. L. Kuijf, J. Li et al., “Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barré and Miller Fisher syndromes,” Infection and Immunity, vol. 75, no. 3, pp. 1245–1254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Fujimoto, B. M. Allos, N. Misawa, C. M. Patton, and M. J. Blaser, “Restriction fragment length polymorphism analysis and random amplified polymorphic DNA analysis of Campylobacter jejuni strains isolated from patients with Guillain-Barré syndrome,” Journal of Infectious Diseases, vol. 176, no. 4, pp. 1105–1108, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. T. M. Wassenaar and D. G. Newell, “Genotyping of Campylobacter spp.,” Applied and Environmental Microbiology, vol. 66, no. 1, pp. 1–9, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. L. N. Nielsen, S. K. Sheppard, N. D. McCarthy, M. C. J. Maiden, H. Ingmer, and K. A. Krogfelt, “MLST clustering of Campylobacter jejuni isolates from patients with gastroenteritis, reactive arthritis and Guillain-Barré syndrome,” Journal of Applied Microbiology, vol. 108, no. 2, pp. 591–599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Piao, M. Minohara, N. Kawamura et al., “Induction of paranodal myelin detachment and sodium channel loss in vivo by Campylobacter jejuni DNA-binding protein from starved cells (C-Dps) in myelinated nerve fibers,” Journal of the Neurological Sciences, vol. 288, no. 1-2, pp. 54–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Kawamura, H. Piao, M. Minohara et al., “Campylobacter jejuni DNA-binding protein from starved cells in Guillain-Barré syndrome patients,” Journal of Neuroimmunology, vol. 240-241, pp. 74–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Bax, M. L. Kuijf, A. P. Heikema et al., “Campylobacter jejuni lipooligosaccharides modulate dendritic cell-mediated T cell polarization in a sialic acid linkage-dependent manner,” Infection and Immunity, vol. 79, no. 7, pp. 2681–2689, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Huizinga, W. van Rijs, J. J. Bajramovic et al., “Sialylation of Campylobacter jejuni endotoxin promotes dendritic cell-mediated B cell responses through CD14-dependent production of IFN-beta and TNF-alpha,” Journal of Immunology, vol. 191, no. 11, pp. 5636–5645, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Phongsisay, “Campylobacter jejuni targets immunoglobulin-like receptor LMIR5,” Molecular Immunology, vol. 63, no. 2, pp. 574–578, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. M. C. Dalakas, “Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies,” Neurology, vol. 59, pp. S13–S21, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. N. M. Van Sorge, L. H. Van Den Berg, K. Geleijns et al., “Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcγ receptors,” Annals of Neurology, vol. 53, no. 5, pp. 570–579, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. W.-L. van der Pol, L. H. van den Berg, R. H. M. Scheepers et al., “IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome,” Neurology, vol. 54, no. 8, pp. 1661–1665, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. N. M. van Sorge, W.-L. van der Pol, M. D. Jansen et al., “Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms,” Journal of Neuroimmunology, vol. 162, no. 1-2, pp. 157–164, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Sang, Q. Chen, X. Liu et al., “Fc receptor like 3 in Chinese patients of Han nationality with Guillain-Barré syndrome,” Journal of Neuroimmunology, vol. 246, no. 1-2, pp. 65–68, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Fekih-Mrissa, M. Mrad, A. Riahi et al., “Association of HLA-DR/DQ polymorphisms with Guillain-Barré syndrome in Tunisian patients,” Clinical Neurology and Neurosurgery, vol. 121, pp. 19–22, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. N. Hasan, H. H. Zalzala, H. R. Mohammedsalih et al., “Association between human leukocyte antigen-DR and demylinating guillain-barré syndrome,” Neurosciences, vol. 19, no. 4, pp. 301–305, 2014. View at Google Scholar · View at Scopus
  27. S. Sinha, K. N. Prasad, D. Jain, K. K. Nyati, S. Pradhan, and S. Agrawal, “Immunoglobulin IgG Fc-receptor polymorphisms and HLA class II molecules in Guillain-Barré syndrome,” Acta Neurologica Scandinavica, vol. 122, no. 1, pp. 21–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Geleijns, G. M. T. Schreuder, B. C. Jacobs et al., “HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome,” Neurology, vol. 64, no. 1, pp. 44–49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Li, J. Yuan, H. Hao, Z. Yan, and S. Wang, “HLA alleles in patients with Guillain-Barre syndrome,” Chinese Medical Journal, vol. 113, no. 5, pp. 429–432, 2000. View at Google Scholar · View at Scopus
  30. J. H. Rees, R. W. Vaughan, E. Kondeatis, and R. A. C. Hughes, “HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection,” Journal of Neuroimmunology, vol. 62, no. 1, pp. 53–57, 1995. View at Publisher · View at Google Scholar · View at Scopus
  31. E. E. Magira, M. Papaioakim, I. Nachamkin et al., “Differential distribution of HLA-DQβ/DRβ epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQβ epitopes associated with susceptibility to and protection from AIDP,” Journal of Immunology, vol. 170, no. 6, pp. 3074–3080, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. D. S. Monos, M. Papaioakim, T. W. Ho, C. Y. Li, and G. M. McKhann, “Differential distribution of HLA alleles in two forms of Guillain-Barré syndrome,” Journal of Infectious Diseases, vol. 176, no. 6, pp. S180–S182, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Blum, P. Csurhes, S. Reddel, J. Spies, and P. McCombe, “Killer immunoglobulin-like receptor and their HLA ligands in Guillain-Barré Syndrome,” Journal of Neuroimmunology, vol. 267, no. 1-2, pp. 92–96, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. L.-Y. Wu, Y. Zhou, C. Qin, and B.-L. Hu, “The effect of TNF-alpha, FcgammaR and CD1 polymorphisms on Guillain-Barré syndrome risk: evidences from a meta-analysis,” Journal of Neuroimmunology, vol. 243, no. 1-2, pp. 18–24, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. K. K. Nyati, K. N. Prasad, A. Verma et al., “Association of TLR4 Asp299Gly and Thr399Ile polymorphisms with Guillain-Barré syndrome in Northern Indian population,” Journal of Neuroimmunology, vol. 218, no. 1-2, pp. 116–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. L. Kuijf, K. Geleijns, N. Ennaji, W. van Rijs, P. A. van Doorn, and B. C. Jacobs, “Susceptibility to Guillain-Barré syndrome is not associated with CD1A and CD1E gene polymorphisms,” Journal of Neuroimmunology, vol. 205, no. 1-2, pp. 110–112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Geleijns, M. Emonts, J. D. Laman et al., “Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome,” Journal of Neuroimmunology, vol. 190, no. 1-2, pp. 127–130, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Geleijns, A. Roos, J. J. Houwing-Duistermaat et al., “Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome,” Journal of Immunology, vol. 177, no. 6, pp. 4211–4217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. C. M. Caporale, F. Papola, M. A. Fioroni et al., “Susceptibility to Guillain-Barré syndrome is associated to polymorphisms of CD1 genes,” Journal of Neuroimmunology, vol. 177, no. 1-2, pp. 112–118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Li, P. Zhao, X. Sun, Y. Che, and Y. Jiang, “Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré syndrome,” Mediators of Inflammation, vol. 2013, Article ID 639712, 9 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Huang, L. Li, S. Liang, and W. Wang, “Conversion of peripheral CD4+CD25- T cells to CD4+CD25+ regulatory T cells by IFN-γ in patients with Guillain-Barré syndrome,” Journal of Neuroimmunology, vol. 217, no. 1-2, pp. 80–84, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. H.-L. Zhang, S. Azimullah, X.-Y. Zheng et al., “IFN-γ deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response,” Journal of Neuroimmunology, vol. 246, no. 1-2, pp. 18–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. V. V. Radhakrishnan, M. G. Sumi, S. Reuben, A. Mathai, and M. D. Nair, “Serum tumour necrosis factor-α and soluble tumour necrosis factor receptors levels in patients with Guillain-Barré syndrome,” Acta Neurologica Scandinavica, vol. 109, no. 1, pp. 71–74, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Deng, X. Yang, T. Jin et al., “The role of IL-12 and TNF-α in AIDP and AMAN,” European Journal of Neurology, vol. 15, no. 10, pp. 1100–1105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. H.-L. Zhang, M. Y. Hassan, X.-Y. Zheng et al., “Attenuated EAN in TNF-alpha deficient mice is associated with an altered balance of M1/M2 macrophages,” PLoS ONE, vol. 7, no. 5, Article ID e38157, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Li, T. Jin, H.-L. Zhang et al., “Circulating Th17, Th22, and Th1 cells are elevated in the guillain-barré syndrome and downregulated by IVIg treatments,” Mediators of Inflammation, vol. 2014, Article ID 740947, 10 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. Z.-Y. Zhang, Z. Zhang, C. Zug, B. Nuesslein-Hildesheim, D. Leppert, and H. J. Schluesener, “AUY954, a selective S1P1 modulator, prevents experimental autoimmune neuritis,” Journal of Neuroimmunology, vol. 216, no. 1-2, pp. 59–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. S.-H. Pelidou, L.-P. Zou, G. Deretzi, C. Oniding, E. Mix, and J. Zhu, “Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role,” Experimental Neurology, vol. 163, no. 1, pp. 165–172, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Jander and G. Stoll, “Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy,” Journal of Neuroimmunology, vol. 114, no. 1-2, pp. 253–258, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Yu, Z. Chen, E. Mix et al., “Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen,” Journal of Neuropathology and Experimental Neurology, vol. 61, no. 7, pp. 614–622, 2002. View at Google Scholar · View at Scopus
  51. R.-S. Duan, X.-M. Zhang, E. Mix, H. C. Quezada, A. Adem, and J. Zhu, “IL-18 deficiency inhibits both Th1 and Th2 cytokine production but not the clinical symptoms in experimental autoimmune neuritis,” Journal of Neuroimmunology, vol. 183, no. 1-2, pp. 162–167, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Hayashi, W. Xiao, M. Kawamoto, O. Yuge, and G. J. Bennett, “Systemic glucocorticoid therapy reduces pain and the number of endoneurial Tumor Necrosis Factor-alpha (TNFα)-positive mast cells in rats with a painful peripheral neuropathy,” Journal of Pharmacological Sciences, vol. 106, no. 4, pp. 559–565, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Dahle, C. Ekerfelt, M. Vrethem, M. Samuelsson, and J. Ernerudh, “T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome,” Journal of the Neurological Sciences, vol. 153, no. 1, pp. 54–60, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. W. Yun, W. Hua-bing, and W. Wei-zhi, “A study of associated cell-mediated immune mechanisms in experimental autoimmune neuritis rats,” Journal of Neuroimmunology, vol. 185, no. 1-2, pp. 87–94, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Hohnoki, A. Inoue, and C.-S. Koh, “Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage,” Journal of Neuroimmunology, vol. 87, no. 1-2, pp. 27–32, 1998. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Press, V. Ozenci, M. Kouwenhoven, and H. Link, “Non-T(H)1 cytokines are augmented systematically early in Guillain-Barré syndrome,” Neurology, vol. 58, no. 3, pp. 476–478, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. K.-M. Myhr, K. S. Vågnes, T. H. Marøy, J. H. Aarseth, H. I. Nyland, and C. A. Vedeler, “Interleukin-10 promoter polymorphisms in patients with Guillain-Barré syndrome,” Journal of Neuroimmunology, vol. 139, no. 1-2, pp. 81–83, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Sivieri, A. M. Ferrarini, F. Lolli et al., “Cytokine pattern in the cerebrospinal fluid from patients with GBS and CIDP,” Journal of the Neurological Sciences, vol. 147, no. 1, pp. 93–95, 1997. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Zhu, H. Link, S. Weerth, C. Linington, E. Mix, and J. Qiao, “The B cell repertoire in experimental allergic neuritis involves multiple myelin proteins and GM1,” Journal of the Neurological Sciences, vol. 125, no. 2, pp. 132–137, 1994. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Deretzi, S. H. Pelidou, L. P. Zou, C. Quiding, and J. Zhu, “Local effects of recombinant rat interleukin-6 on the peripheral nervous system,” Immunology, vol. 97, no. 4, pp. 582–587, 1999. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Bao, J. U. Lindgren, P. van der Meide, S. W. Zhu, H.-G. Ljunggren, and J. Zhu, “The critical role of IL-12p40 in initiating, enhancing, and perpetuating pathogenic events in murine experimental autoimmune neuritis,” Brain Pathology, vol. 12, no. 4, pp. 420–429, 2002. View at Google Scholar · View at Scopus
  62. Z.-Y. Zhang, Z. Zhang, U. Fauser, and H. J. Schluesener, “Expression of interleukin-16 in sciatic nerves, spinal roots and spinal cords of experimental autoimmune neuritis rats,” Brain Pathology, vol. 19, no. 2, pp. 205–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Creange, L. Belec, B. Clair, J.-D. Degos, J.-C. Raphael, and R. K. Gherardi, “Circulating transforming growth factor beta 1 (TGF-β1) in Guillain-Barre syndrome: decreased concentrations in the early course and increase with motor function,” Journal of Neurology Neurosurgery and Psychiatry, vol. 64, no. 2, pp. 162–165, 1998. View at Publisher · View at Google Scholar · View at Scopus
  64. L. M. Ossege, E. Sindem, B. Voss, and J. P. Malin, “Expression of TNFalpha and TGFbeta1 in Guillain-Barré syndrome: correlation of a low TNFalpha-/TGFbeta1-mRNA ratio with good recovery and signs for immunoregulation within the cerebrospinal fluid compartment,” European Journal of Neurology, vol. 7, pp. 17–25, 2000. View at Google Scholar
  65. T. Saida, K. Saida, R. P. Lisak, M. J. Brown, D. H. Silberberg, and A. K. Asbury, “In vivo demyelinating activity of sera from patients with Guillain-Barre syndrome,” Annals of Neurology, vol. 11, no. 1, pp. 69–75, 1982. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Sawant-Mane, M. B. Clark, and C. L. Koski, “In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes,” Annals of Neurology, vol. 29, no. 4, pp. 397–404, 1991. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Kuwabara and N. Yuki, “Axonal Guillain-Barré syndrome: concepts and controversies,” The Lancet Neurology, vol. 12, no. 12, pp. 1180–1188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. S. K. Halstead, F. M. P. Zitman, P. D. Humphreys et al., “Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model,” Brain, vol. 131, no. 5, pp. 1197–1208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. M. C. Dalakas, “The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile,” Pharmacology and Therapeutics, vol. 102, no. 3, pp. 177–193, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. S. D'Aguanno, D. Franciotta, S. Lupisella et al., “Protein profiling of Guillain-Barrè syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry,” Neuroscience Letters, vol. 485, no. 1, pp. 49–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. C. E. Hafer-Macko, K. A. Sheikh, C. Y. Li et al., “Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy,” Annals of Neurology, vol. 39, no. 5, pp. 625–635, 1996. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Hafer-Macko, S.-T. Hsieh, C. Yan Li et al., “Acute motor axonal neuropathy: an antibody-mediated attack on axolemma,” Annals of Neurology, vol. 40, no. 4, pp. 635–644, 1996. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Susuki, N. Yuki, D. P. Schafer et al., “Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies,” Experimental Neurology, vol. 233, no. 1, pp. 534–542, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. M. E. Sanders, C. L. Koski, D. Robbins, M. L. Shin, M. M. Frank, and K. A. Joiner, “Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis,” Journal of Immunology, vol. 136, no. 12, pp. 4456–4459, 1986. View at Google Scholar · View at Scopus
  75. C. L. Koski, M. E. Sanders, P. T. Swoveland et al., “Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies,” The Journal of Clinical Investigation, vol. 80, no. 5, pp. 1492–1497, 1987. View at Publisher · View at Google Scholar · View at Scopus
  76. G. A. Putzu, D. Figarella-Branger, C. Bouvier-Labit, A. Liprandi, N. Bianco, and J. F. Pellissier, “Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barre Syndrome,” Journal of the Neurological Sciences, vol. 174, no. 1, pp. 16–21, 2000. View at Publisher · View at Google Scholar · View at Scopus
  77. K. A. Langert, C. L. Von Zee, and E. B. Stubbs Jr., “Tumour necrosis factor α enhances CCL2 and ICAM-1 expression in peripheral nerve microvascular endoneurial endothelial cells,” ASN Neuro, vol. 5, no. 1, Article ID e00104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. R. H. Xia, N. Yosef, and E. E. Ubogu, “Selective expression and cellular localization of pro-inflammatory chemokine ligand/receptor pairs in the sciatic nerves of a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome,” Neuropathology and Applied Neurobiology, vol. 36, no. 5, pp. 388–398, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. D. Orlikowski, B. Chazaud, A. Plonquet et al., “Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barré syndrome and experimental autoimmune neuritis,” Journal of Neuroimmunology, vol. 134, no. 1-2, pp. 118–127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. B. C. Kieseier, M. Tani, D. Mahad et al., “Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10,” Brain, vol. 125, no. 4, pp. 823–834, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Luongo, M. Sajic, J. Grist, A. K. Clark, S. Maione, and M. Malcangio, “Spinal changes associated with mechanical hypersensitivity in a model of Guillain-Barré syndrome,” Neuroscience Letters, vol. 437, no. 2, pp. 98–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Kastenbauer, U. Koedel, M. Wick, B. C. Kieseier, H.-P. Hartung, and H.-W. Pfister, “CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system,” Journal of Neuroimmunology, vol. 137, no. 1-2, pp. 210–217, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. L.-P. Zou, S.-H. Pelidou, N. Abbas et al., “Dynamics of production of MIP-1α, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats,” Journal of Neuroimmunology, vol. 98, no. 2, pp. 168–175, 1999. View at Publisher · View at Google Scholar · View at Scopus
  84. P. P. Sainaghi, L. Collimedaglia, F. Alciato et al., “The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy,” Cytokine, vol. 51, no. 2, pp. 138–143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. C. Fokke, B. van den Berg, J. Drenthen, C. Walgaard, P. A. van Doorn, and B. C. Jacobs, “Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria,” Brain, vol. 137, no. 1, pp. 33–43, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. H.-L. Zhang, X.-M. Zhang, X.-J. Mao et al., “Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy,” Acta Neurologica Scandinavica, vol. 125, no. 2, pp. 129–135, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Gonzalez-Quevedo, R. F. Carriera, Z. L. O'Farrill, I. S. Luis, R. M. Becquer, and R. S. Luis Gonzalez, “An appraisal of blood-cerebrospinal fluid barrier dysfunction during the course of Guillain Barré syndrome,” Neurology India, vol. 57, no. 3, pp. 288–294, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. H.-L. Chiang, R.-K. Lyu, M.-Y. Tseng et al., “Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders,” Clinica Chimica Acta, vol. 405, no. 1-2, pp. 143–147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. X.-K. Wang, H.-L. Zhang, F.-H. Meng et al., “Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barré syndrome,” Neurological Sciences, vol. 34, no. 5, pp. 655–661, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Mokuno, K. Kiyosawa, K. Sugimura et al., “Prognostic value of cerebrospinal fluid neuron-specific enolase and S-100b protein in Guillain-Barre syndrome,” Acta Neurologica Scandinavica, vol. 89, no. 1, pp. 27–30, 1994. View at Google Scholar · View at Scopus
  91. Y.-R. Yang, S.-L. Liu, Z.-Y. Qin et al., “Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barré syndrome,” Cellular and Molecular Neurobiology, vol. 28, no. 5, pp. 737–744, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Nagai, Y. Murakawa, M. Terashima et al., “Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases,” Neurology, vol. 55, no. 12, pp. 1828–1832, 2000. View at Publisher · View at Google Scholar · View at Scopus
  93. Y.-C. Huang, R.-K. Lyu, M.-Y. Tseng et al., “Decreased intrathecal synthesis of prostaglandin D2 synthase in the cerebrospinal fluid of patients with acute inflammatory demyelinating polyneuropathy,” Journal of Neuroimmunology, vol. 206, no. 1-2, pp. 100–105, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Nishino, T. Kanbayashi, N. Fujiki et al., “CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies,” Neurology, vol. 61, no. 6, pp. 823–825, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Jin, L.-S. Hu, M. Chang, J. Wu, B. Winblad, and J. Zhu, “Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients,” European Journal of Neurology, vol. 14, no. 5, pp. 563–568, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. N. Shahrizaila, N. Kokubun, S. Sawai et al., “Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes,” Neurology, vol. 83, no. 2, pp. 118–124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. J. K. Kim, J. S. Bae, D.-S. Kim et al., “Prevalence of anti-ganglioside antibodies and their clinical correlates with Guillain-Barré syndrome in Korea: a nationwide multicenter study,” Journal of Clinical Neurology, vol. 10, no. 2, pp. 94–100, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. C. W. Ang, N. Yuki, B. C. Jacobs et al., “Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GalNAc-GD1a antibodies,” Neurology, vol. 53, no. 9, pp. 2122–2127, 1999. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Hitoshi, S. Kusunoki, K. Kon et al., “A novel ganglioside, 9-O-acetyl GD1b, is recognized by serum antibodies in Guillain-Barré syndrome,” Journal of Neuroimmunology, vol. 66, no. 1-2, pp. 95–101, 1996. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Koga, N. Yuki, T. Ariga, and K. Hirata, “Antibodies to GD3, GT3, and O-acetylated species in Guillain-Barré and Fisher's syndromes: their association with cranial nerve dysfunction,” Journal of the Neurological Sciences, vol. 164, no. 1, pp. 50–55, 1999. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Kaida, K. Kamakura, G. Ogawa et al., “GD1b-specific antibody induces ataxia in Guillain-Barré syndrome,” Neurology, vol. 71, no. 3, pp. 196–201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Chiba, S. Kusunoki, H. Obata, R. Machinami, and I. Kanazawa, “Serum anti-GQ(1b) IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies,” Neurology, vol. 43, no. 10, pp. 1911–1917, 1993. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Kuwahara, S. Suzuki, K. Takada, and S. Kusunoki, “Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy,” Journal of Neuroimmunology, vol. 239, no. 1-2, pp. 87–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Kaida, D. Morita, M. Kanzaki et al., “Anti-ganglioside complex antibodies associated with severe disability in GBS,” Journal of Neuroimmunology, vol. 182, no. 1-2, pp. 212–218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. K.-I. Kaida, D. Morita, M. Kanzaki et al., “Ganglioside complexes as new target antigens in Guillain-Barré syndrome,” Annals of Neurology, vol. 56, no. 4, pp. 567–571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. G. Ogawa, K.-I. Kaida, M. Kuwahara, F. Kimura, K. Kamakura, and S. Kusunoki, “An antibody to the GM1/GalNAc-GD1a complex correlates with development of pure motor Guillain-Barré syndrome with reversible conduction failure,” Journal of Neuroimmunology, vol. 254, no. 1-2, pp. 141–145, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Rinaldi, K. M. Brennan, G. Kalna et al., “Antibodies to heteromeric glycolipid complexes in guillain-barré syndrome,” PLoS ONE, vol. 8, no. 12, Article ID e82337, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Bersano, M. Fiorini, S. Allaria et al., “Detection of CSF 14-3-3 protein in Guillain-Barré syndrome,” Neurology, vol. 67, no. 12, pp. 2211–2216, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. Y. Sekiguchi, A. Uncini, N. Yuki et al., “Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 83, no. 1, pp. 23–28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. B. C. Jacobs, M. Koga, W. van Rijs et al., “Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome,” Journal of Neuroimmunology, vol. 194, no. 1-2, pp. 181–190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. J. J. Devaux, M. Odaka, and N. Yuki, “Nodal proteins are target antigens in Guillain-Barré syndrome,” Journal of the Peripheral Nervous System, vol. 17, no. 1, pp. 62–71, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. J. J. Devaux, “Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of ranvier,” The American Journal of Pathology, vol. 181, no. 4, pp. 1402–1413, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. W. Yan, T. Nguyen, N. Yuki et al., “Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis,” Journal of Neuroimmunology, vol. 277, no. 1-2, pp. 13–17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  114. C. M. Gabriel, N. A. Gregson, and R. A. C. Hughes, “Anti-PMP22 antibodies in patients with inflammatory neuropathy,” Journal of Neuroimmunology, vol. 104, no. 2, pp. 139–146, 2000. View at Publisher · View at Google Scholar · View at Scopus
  115. A. Makowska, J. Pritchard, L. Sanvito et al., “Immune responses to myelin proteins in Guillain-Barré syndrome,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 6, pp. 664–671, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. H. R. Inglis, P. A. Csurhes, and P. A. McCombe, “Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 78, no. 4, pp. 419–422, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. G. Sessa, R. Nemni, N. Canal, and P. C. Marchisio, “Circulating fragments of myelin-associated α6β4 integrin in guillain-barre syndrome,” Journal of Neuroimmunology, vol. 80, no. 1-2, pp. 115–120, 1997. View at Publisher · View at Google Scholar · View at Scopus
  118. G. Nakos, E. Tziakou, L. Maneta-Peyret, C. Nassis, and M. E. Lekka, “Anti-phospholipid antibodies in serum from patients with Guillain-Barré syndrome,” Intensive Care Medicine, vol. 31, no. 10, pp. 1401–1408, 2005. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Samukawa, Y. Hamada, M. Kuwahara et al., “Clinical features in Guillain-Barré syndrome with anti-Gal-C antibody,” Journal of the Neurological Sciences, vol. 337, no. 1-2, pp. 55–60, 2014. View at Publisher · View at Google Scholar
  120. I. Dujmovic, M. P. Lunn, M. M. Reilly, and A. Petzold, “Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barré syndrome,” Muscle & Nerve, vol. 48, no. 1, pp. 132–134, 2013. View at Publisher · View at Google Scholar · View at Scopus
  121. J. Gaiottino, N. Norgren, R. Dobson et al., “Increased neurofilament light chain blood levels in neurodegenerative neurological diseases,” PLoS ONE, vol. 8, no. 9, Article ID e75091, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. M. S. Maddur, J. Trinath, M. Rabin et al., “Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation,” Cellular & Molecular Immunology, vol. 12, no. 5, pp. 650–652, 2014. View at Publisher · View at Google Scholar
  123. C. Galeotti, S. V. Kaveri, and J. Bayry, “Molecular and immunological biomarkers to predict IVIg response,” Trends in Molecular Medicine, vol. 21, pp. 145–147, 2015. View at Publisher · View at Google Scholar · View at Scopus